Tanezumab
Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor. It was developed by Pfizer as a treatment for pain.[1]
In 2009 there was a Phase III trial for knee pain due to osteoarthritis (OA).[2]
Another phase III trial for hip pain in OA [3] was halted in June 2010 when some patients needed hip replacement.[4]
Tanezumab is undergoing Phase II clinical trials for the treatment of various pain entities, including chronic low back pain, bone cancer pain, and interstitial cystitis.[5]
In march of 2012 the Anti-NGF Testing - FDA Committee voted in favor of a continuation of the development of nerve-blocking medications, as long as certain safety precautions were observed.
A phase III trial published in 2013 found tanezumab was superior to placebo for painful hip osteoarthritis.[6]
References
External links
|
---|
| CNTF | |
---|
| LNGF | |
---|
| RET | |
---|
| Trk | | |
---|
| |
- Agonists: 3,7-DHF
- 3,7,8,2'-THF
- 4'-DMA-7,8-DHF
- 7,3'-DHF
- 7,8-DHF
- 7,8,2'-THF
- 7,8,3'-THF
- Amitriptyline
- BDNF
- Deoxygedunin
- Diosmetin
- HIOC
- LM22A-4
- N-Acetylserotonin
- NT-3
- NT-4
- Norwogonin (5,7,8-THF)
- R7
- TDP6
|
---|
| | |
---|
|
---|
| Others | |
---|
|